Related Experiment Video
Updated: Jul 24, 2025
Real-time Cytotoxicity Assays in Human Whole Blood
Published on: November 7, 2014
Establishing a novel and sensitive assay for bioactivity determination of anti-CD25 antibodies
Maoqin Duan1, Chuanfei Yu1, Yalan Yang1
1Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech, Division of Monoclonal Antibody Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Abstract:
Anti-CD25 antibodies have been approved for renal transplantation and has been used prior to and during transplantation by the Food and Drug Administration (FDA). However, no reported bioassays have been reflected the mechanism of action (MOA) of anti-CD25 antibodies. Here, we describe the development and validation of a reporter gene assay (RGA) based on the engineered C8166-STAT5RE-Luc cells expressing endogenous IL-2 receptors and a STAT5-inducible element-driven firefly luciferase in C8166 cell lines. The RGA was fully validated according to the International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for the Human Use-Q2 (ICH-Q2). After optimization, the assay showed excellent specificity, linearity, accuracy, precision, and robustness. Due to the MOA relatedness and the excellent assay performance, the RGA is suitable for exploring the critical quality attributes (CQAs), release inspection, comparability and stability of anti-CD25 mAbs.
Insights
A new reporter gene assay (RGA) was developed to measure the mechanism of action of anti-CD25 antibodies, crucial for renal transplantation. This validated assay supports quality control for anti-CD25 monoclonal antibodies (mAbs).
Area of Science:
- Immunology
- Biotechnology
- Pharmacology
Background:
- Anti-CD25 antibodies are FDA-approved for renal transplantation.
- Existing bioassays do not reflect the mechanism of action (MOA) of anti-CD25 antibodies.
Purpose of the Study:
- To develop and validate a reporter gene assay (RGA) for anti-CD25 antibodies.
- To establish a bioassay reflecting the MOA of anti-CD25 antibodies.
Main Methods:
- Development of an RGA using engineered C8166-STAT5RE-Luc cells.
- Validation of the RGA according to ICH-Q2 guidelines.
- Optimization of the assay for specificity, linearity, accuracy, precision, and robustness.
Main Results:
- The RGA demonstrated excellent performance characteristics.
- The assay is suitable for assessing critical quality attributes (CQAs).
- The RGA can be used for release testing, comparability, and stability studies of anti-CD25 mAbs.
Conclusions:
- The validated RGA effectively measures the MOA of anti-CD25 antibodies.
- This assay is a valuable tool for quality control in the manufacturing of anti-CD25 mAbs.
- The RGA supports the development and regulatory approval of anti-CD25 antibody therapies.
More Related Videos
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023